Pegcetacoplan

Pegcetacoplan Uses, Dosage, Side Effects, Food Interaction and all others data.

Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody eculizumab. Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization. Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5. Pegcetacoplan is a pegylated C3 inhibitor that can disrupt the processes leading to both forms of hemolysis that threaten patients with PNH.

Pegcetacoplan was granted FDA approval on 14 May 2021.

Pegcetacoplan is a complement C3 inhibitor that prevents complement-mediated hemolysis of red blood cells in patients with paroxysomal nocturnal hemoglobinuria. It has a long duration of action as it is administered twice weekly. Patients should be vaccinated against encapsulated bacteria according to the most recent recommendations.

Pegcetacoplan
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Pegcetacoplan
Availability	Prescription only
Generic	Pegcetacoplan
Pegcetacoplan Other Names	Pegcetacoplan
Related Drugs	Soliris, Ultomiris, eculizumab, ravulizumab, Empaveli
Type
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Pegcetacoplan is a complement inhibitor indicated in the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Pegcetacoplan is indicated to treat adults with paroxysmal nocturnal hemoglobinuria (PNH).

Pegcetacoplan is also used to associated treatment for these conditions: Paroxysmal Nocturnal Haemoglobinuria (PNH)

How Pegcetacoplan works

PNH is due to a mutation in the phosphatidylinositol N-acetylglucosaminyltransferase subunit A (PIGA) gene. The mutation in the PIGA gene prevents an early step in the formation of glycosyl phosphatidyl inositol (GPI). Under normal circumstances, GPI connects cell surface proteins to the cell. In patients with PNH, complement inhibiting cell surface proteins, such as CD55 and CD59, are not anchored to the surface of red blood cells. In cases with reduced or absent CD55 and CD59, complement is not appropriately inhibited, leading to activation of the complement system and complement-mediated hemolysis. As a result of complement-mediated hemolysis, patients with PNH may experience anemia, fatigue, asthenia, and dyspnea.

The alternative complement system pathway is spontaneously activated due to the absence of CD55, leading to activation of a C3 convertase that that cleaves C3 into C3a and C3b. C3b binds to factor B, which is cleaved by factor D into the smaller Ba and larger Bb. The resulting C3bBb can bind to other C3 proteins, leading to a positive feedback loop of complement activation. C3b proteins can also bind directly to a target cell, marking it as a target for phagocytosis. CD55, also known as decay-accelerating factor (DAF) disrupts the formation of C3bBb, preventing spontaneous activation of the alternative complement pathway.

C3b cleaves C5 into C5a and C5b. C5b combines with complement proteins C6, C7, C8, and C9 to form the membrane attack complex (MAC). The MAC is a pore formed in the cell by 16 C9 proteins associated with C5b, C6, C7, and C8. Formation of pores destroys the cell membrane leading to cell death. CD59 disrupts the formation of the MAC, preventing hemolysis.

In patients with PNH, extravascular hemolysis is mediated by C3b marking red blood cells for phagocytosis, and intravascular hemolysis is mediated by the MAC. Pegcetacoplan binds to C3 and C3b, reducing cleavage and activation of complement pathways, reducing both extravascular and intravascular hemolysis.

Toxicity

Data regarding overdoses in humans are not readily available. In the case of an overdose, patients should be treated with symptomatic and supportive measures.